{"result": "(\"entity\"<|>FQ<|>ORGANIZATION<|>FQ refers to the consensus on nutrition for patients with cystic fibrosis, providing guidelines on dietary needs and supplementation.)\n##\n(\"entity\"<|>KREON<|>ORGANIZATION<|>Kreon is a medication used to provide pancreatic enzymes for patients with exocrine pancreatic insufficiency.)\n##\n(\"entity\"<|>VITAMINS<|>ORGANIZATION<|>Vitamins are essential nutrients recommended for both children and adults, with specific dosages outlined for various age groups.)\n##\n(\"entity\"<|>MCT<|>ORGANIZATION<|>MCT refers to medium-chain triglycerides, which are used as supplements in enteral nutrition.)\n##\n(\"entity\"<|>PANCREATIC ENZYMES<|>ORGANIZATION<|>Pancreatic enzymes are treatments for patients with exocrine pancreatic insufficiency, aiding in digestion.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support is indicated for patients with specific weight and health criteria, ensuring adequate nutrient intake.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPLEMENTATION<|>EVENT<|>Nutritional supplementation involves providing additional nutrients to patients, particularly those with cystic fibrosis.)\n##\n(\"relationship\"<|>FQ<|>VITAMINS<|>FQ provides guidelines on the administration of vitamins for patients with cystic fibrosis<|>7)\n##\n(\"relationship\"<|>KREON<|>PANCREATIC ENZYMES<|>Kreon is a preparation that contains pancreatic enzymes for treating exocrine pancreatic insufficiency<|>8)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPORT<|>FQ<|>FQ outlines the criteria for when nutritional support is necessary for patients<|>6)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPLEMENTATION<|>FQ<|>FQ discusses the importance of nutritional supplementation for patients with cystic fibrosis<|>6)\n##\n(\"relationship\"<|>MCT<|>NUTRITIONAL SUPPLEMENTATION<|>MCTs are used as supplements in enteral nutrition to enhance caloric intake<|>5)\n##\n(\"relationship\"<|>PANCREATIC ENZYMES<|>NUTRITIONAL SUPPORT<|>Pancreatic enzymes are part of the nutritional support strategy for patients with exocrine pancreatic insufficiency<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: |-------------|\n| Normal               | >80%    | 0           |\n| Disfunción moderada  | 40-80%  | 0,2         |\n| Afectación severa    | <40%    | 0,3-0,35    |\n\nEl Coeficiente de absorción grasa= Grasa ingerida-Grasa eliminada/Grasa ingerida x100, siendo normal >93% (0,93) y patológico <93%\n\nEl aporte suplementario de energía debe de intentar realizarse con alimentos naturales, fragmentando el número de comidas a no menos de 5 diarias.\n\n#### Distribución de macronutrientes\n\nLos consensos sobre nutrición en FQ aconsejan que un 35-40% de la energía se aporte como grasas, un 40-48% como carbohidratos y un 15-20% como proteínas. Los pacientes con FQ presentan un perfil lipídico con deficiencia en ácidos grasos esenciales y especialmente docosahexaenoico (DHA) y eicosapentanoico (EPA) con mayor tendencia a la síntesis de eicosanoides proinflamatorios. Se está investigando el efecto de la suplementación dietética con ácidos grasos omega6 y omega 3, así como con DHA y EPA para favorecer la síntesis de proteínas con menor capacidad proinflamatoria. De momento solo se aconseja alto consumo de pescado, aceite de borraja, etc.\n\n#### Suplementos de micronutrientes\n\nTanto consenso europeo como el americano aconsejan la administración sistemática de vitaminas liposolubles (tabla 2). Las dosis aconsejadas deben de individualizarse, monitorizando las mismas al menos 1 vez al año.\n\n178\n---\n| Vitaminas | Niños | Adultos |\n|-----------|--------|---------|\n| A | 3000-10000UI/día | 4000-10000UI/día |\n| D | vit D 800 UI/ día | vit D 800 UI/ día |\n| K | Menores 1 año: 2,5mg/semana | 1mg/día-10mg/semana |\n|   | Mayores 1 año: 5mg/2días |  |\n| E | 0-6 meses: 25UI/día | 200-400mg/día |\n|   | 6-12 meses: 50UI/día |  |\n|   | 1-4 años: 100UI/día |  |\n|   | 4-10 años: 100-200UI/día |  |\n|   | >10 años: 200-400UI/día |  |\n\nEnzimas pancreáticas\nLos pacientes con insuficiencia pancreática exocrina (IPE) deben de ser tratados con\nenzimas pancreáticas. Deben de administrarse durante las comidas. Se aconseja\nentre 500 y 4000 UI de lipasa por gramo de grasa ingerida, no sobrepasando las\n10000 UI de lipasa por Kg de peso corporal al día o 2500 UI de lipasa/Kg/dosis. Se\nemplea el preparado Kreon (10000 o 25000).\nLa dosis se ajustan evaluando el coeficiente de absorción grasa. Cuando a pesar de\nlas enzimas no se consigue minimizar la esteatorrea puede ser necesaria la adminis-\ntración de antisecretores o descartar sobrecrecimiento bacteriano.\n\nIndicaciones de soporte nutricional\n\n-Cuando el IMC es inferior al percentil 25 en niños y a 18,5 en adultos\n\n-En niños con estacionamiento ponderal en dos controles sucesivos\n\n-En cualquier edad si la perdida ponderal es >5% en dos meses.\n\n-Pacientes normonutridos en los que se prevé una alimentación oral insuficiente\nmás de 7 días.\n\n-Riesgo de desnutrición por infección grave y/o tratamiento agresivo cuya ingesta\nno cubre el 75% de las recomendaciones.\n\nNutrición enteral\nPueden utilizarse suplementos como módulos grasos (MCT) o nutrición enteral con\nfórmulas poliméricas normo o hipercalóricas de forma intermitente. Siempre que\nsea posible se utilizara la vía oral. En caso de desnutrición grave se planteara nutri-\nción invasiva ( por sonda nasogástrica o PEG) continua o intermitente. Las enzimas\npancreáticas deben de administrarse antes y al final de la administración. En caso\nde administración continua lo ideal es administrar las enzimas cada 3-4 horas. La\nabsorción de una dieta elemental sin aportar enzimas es similar a la de una dieta\npolimérica aportando enzimas por lo que no se recomienda la asociación de trata-\nmiento enzimático cuando se utilicen dichas dietas.\n---\nNutrición parenteral\nSolo estaría indicada en las escasas situaciones en las que el tracto gastrointestinal no está funcionante. En casos excepcionales de pacientes\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}